![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
|
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
576kB | |
|
PDF (Authors’ Original Submitted Files for Images)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
139kB |
| Item Type: | Review |
|---|---|
| Title: | Development of prophylactic vaccines against HIV-1 |
| Creators Name: | Schiffner, T. and Sattentau, Q.J. and Dorrell, L. |
| Abstract: | The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions. |
| Keywords: | Vaccine Design, Step Trial, Venezuelan Equine Encephalitis Virus, Modify Vaccinia Ankara, Elite Controller |
| Source: | Retrovirology |
| ISSN: | 1742-4690 |
| Publisher: | BioMed Central |
| Volume: | 10 |
| Page Range: | 72 |
| Date: | 17 July 2013 |
| Official Publication: | https://doi.org/10.1186/1742-4690-10-72 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
Download Statistics
Download Statistics
